Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.
Allurion Technologies Inc (ALUR) delivers innovative weight management solutions through its swallowable gastric balloon and integrated digital platform. This page provides authorized updates on corporate developments, clinical advancements, and strategic initiatives shaping the future of non-invasive obesity treatment.
Investors and healthcare professionals will find timely announcements including quarterly earnings reports, FDA regulatory updates, partnerships with medical institutions, and new clinical study findings. Our curated news collection ensures transparent access to material events affecting the company's position in the medical device sector.
Key content categories include product innovation timelines, peer-reviewed research publications, executive leadership changes, and global expansion updates. Each announcement is sourced directly from official corporate communications to maintain accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to Allurion's latest developments in AI-powered patient monitoring systems and procedure-less weight loss technologies. Regularly updated to reflect the company's progress in merging medical devices with digital health solutions.
Allurion Technologies (NYSE: ALUR) reported Q2 2024 financial results, showing strong sequential revenue growth and record procedure volume. Key highlights include:
- Q2 revenue of $11.8 million, up 25% from Q1 2024
- Loss from operations reduced by 30% year-over-year
- Procedure volume grew 12% year-over-year, with over 10,000 balloon placements
- Updated 2024 revenue guidance to $40-$45 million
- Completed public offering raising $22 million in gross proceeds
The company faced a setback in France with the suspension of Allurion Balloon sales but is working on a remediation plan. Allurion aims to achieve profitability by the end of 2025 and continues to innovate, including expanding AI-powered weight loss coach capabilities.
Allurion Technologies, Inc. (NYSE: ALUR), a company focused on ending obesity, has announced that it will release its second quarter 2024 financial results on Tuesday, August 13, 2024. The company will host a conference call and live audio webcast on the same day at 8:30 AM ET to discuss the results and provide a business update.
Investors can access the conference call by dialing (888) 330-3417 (domestic) or +1 646 960 0804 (international) using Conference ID 1905455. The live audio webcast will be available on the Events section of Allurion's Investor Relations website. A replay of the call will be accessible by phone using Access Code 1905455, and the archived webcast will be available on the company's website.
Allurion Technologies has announced the pricing of a $20 million public offering and concurrent private placement. The company will issue 14,406,508 shares and an equal number of warrants at $1.20 per share, generating $17.3 million in gross proceeds. An additional $2.7 million will come from the sale of Series A convertible preferred stock and private placement warrants to RTW Investments. The total expected gross proceeds from these offerings are $20 million. The funds will support clinical trials, commercial sales, R&D, and general corporate purposes. The offerings are anticipated to close by July 1, 2024, pending customary conditions.
Allurion Technologies (NYSE: ALUR) has launched a public offering of up to $20 million in common stock and warrants. The offering is managed by Jefferies and TD Cowen, with Roth Capital Partners co-managing. Allurion plans to use the proceeds for clinical trials, commercial sales, R&D, and general corporate purposes. Additionally, RTW Investments has shown interest in purchasing up to $3 million of the securities, potentially through a concurrent private placement of Series A convertible preferred stock. The offering is contingent on SEC registration approval.
Allurion Technologies (NYSE: ALUR) published new data showing that patients on the Allurion Program gained an average of 5.6% lean mass while losing 14% body weight over four months. The study included 571 patients tracked using the Allurion App, Connected Scale, and Health Tracker, supported by the AI-driven Allurion Virtual Care Suite. On average, patients reduced their weight from 97.9kg to 84.0kg and increased lean mass from 49.8kg to 52.6kg. Higher activity patients achieved a greater weight loss (15.6kg) and more significant lean mass gains (2.8kg) compared to lower activity patients. The body fat percentage also decreased from 32.7% to 27.9%. This study contrasts with GLP-1 therapy results, which typically show lean mass loss ranging from 3-11%, highlighting the potential of real-time body composition monitoring and personalized recommendations.
Allurion Technologies (NYSE: ALUR) presented new data at the American Society for Metabolic and Bariatric Surgery Annual Meeting, showing a 22.1% weight loss at one year with its Allurion Balloon, surpassing the 15.4-16.2% weight loss achieved by 12-month endoscopic balloons. The study involved 121 patients across 11 obesity centers. Additional presentations highlighted the Allurion Balloon's low intolerance rate (1-3%) compared to other balloons (14.4%), and a 10-fold decrease in serious adverse events. The AI-powered Coach Iris received high satisfaction scores, with 84% for Fidelity, 79% for Accuracy, 89% for Safety, and 95% for Tone. Other topics included digital tracking of hunger and fullness.
Allurion Technologies (NYSE: ALUR) has appointed Ojas A. Buch as Chief Operating Officer, effective June 3, 2024. Buch will oversee Research and Development, Manufacturing, Operations, Quality and Regulatory, and Business Development and Innovation functions. He brings 25 years of experience in the healthcare industry, having held leadership roles at GE Healthcare, St Jude Medical (Abbott), CareFusion (Vyaire), Philips, and PENTAX Medical – Americas. His appointment aims to help Allurion achieve significant milestones and scale sustainably. Dr. Shantanu Gaur, Allurion’s Founder and CEO, emphasized Buch's strategic mindset and leadership skills as critical to Allurion's growth and innovation in the weight loss solutions market.
Allurion Technologies (NYSE: ALUR) has expanded its AI-powered weight loss coach, Coach Iris, to support patients on GLP-1s and other anti-obesity medications. This enhancement provides 24/7 personalized coaching on treatment duration, side effects, and lifestyle modifications. In addition, the company announced its first commercial agreements for its Virtual Care Suite (VCS) in the U.S.
The VCS integrates remote patient monitoring, predictive analytics, telehealth, and care team collaboration, and is designed for healthcare providers offering various weight loss therapies. Medical professionals like Dr. Christopher McGowan and Dr. Alexander Shapsis have adopted VCS, praising its ability to deliver personalized care and improve patient engagement.
According to Blue Cross Blue Shield, a substantial portion of patients discontinue GLP-1s prematurely, underscoring the need for better patient management. An Allurion study found that the VCS improved patient accountability, practice efficiency, and engagement.
Allurion Technologies (NYSE: ALUR) has announced its participation in two major investor conferences: the Jefferies Global Healthcare Conference and the Sidoti Small Cap Virtual Conference in June 2024.
The company aims to discuss its strategic initiatives, latest financial performance, and long-term growth plans at these events.
Allurion Technologies (NYSE: ALUR) announced three presentations at the European Congress on Obesity (ECO) held from May 12-15, 2024, in Venice, Italy. The presentations highlighted data from a study involving 712 patients across six obesity centers, demonstrating an average total body weight loss (TBWL) of 14.1% in four months, with 70% of the weight loss from fat mass and only 30% from lean body mass. The Allurion Program, which includes the Allurion Balloon and Virtual Care Suite, aims to preserve lean body mass during weight loss. Additionally, previous studies showed that more intensive programs led to 100% fat mass-derived weight loss without muscle mass loss. The presentations also covered behavior change coaching and the positive impact of GLP-1s on the program.
